rigosertib sodium + oxaliplatin

rigosertib sodium + oxaliplatin is an investigational combination of two distinct antineoplastic agents used in early-phase clinical research for cancer. - **Rigosertib sodium (ON-01910.Na):** A synthetic benzyl styryl sulfone small molecule, acts as a multi-kinase inhibitor with a complex mechanism, disrupting multiple signaling pathways involved in cell cycle progression and mitosis, leading to mitotic arrest and apoptosis. It is primarily being studied for myelodysplastic syndrome and solid tumors[1][3][4]. - **Oxaliplatin:** A third-generation platinum-based chemotherapeutic, functions as a DNA synthesis inhibitor by forming DNA crosslinks, which halt replication and transcription, inducing apoptosis. It is a standard agent in colorectal cancer therapy[5][6]. The combination has demonstrated enhanced antitumor activity versus monotherapy in preclinical models of *KRAS* mutant colorectal cancer, with synergy attributed to complementary mechanisms of action. Both intravenous agents are typically administered in early-phase (Phase I) clinical trials in patients with advanced or refractory solid tumors[1][4].

Brand names

Eloxatin

Other names

rigosertib sodium + oxaliplatinRGS + OXA